Presented by

BPCI BPCI
IPHA IPHA
NIBRT NIBRT

Event sponsors

McKesson McKesson
PwC PwC

Agency partners

Enterprise Ireland Enterprise Ireland
IDA Ireland IDA Ireland
InterTrade Ireland InterTrade Ireland
Science Foundation Ireland Science Foundation Ireland

Day 2 Plenary Session


08:00
Delegate registration with light refreshments
Session 1: Partnerships for Unlocking the Value of Innovation
09:00
The Promise of Industry-Government-Academic Partnerships
Professor Mark Lawler, Associate Pro-Vice-Chancellor and Professor of Digital Health in the Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast
09:30
Lightening Presentation from Avectas
09:45
The Convergence of Technology and Life Sciences
Jim O’Donoghue, President, S3 Connected Health
10:15
The Changing Paradigm: Regulators as Enablers
Dr Lorraine Nolan, Chief Executive, HPRA
10:45
Panel discussion
11:00
Networking coffee break
11:30
Lightening Presentation from Inflazome
Session 2: Thematic Presentations and Moderated Discussions
11:45
Connected Health
These presentations and the discussion explore the convergence of software, technology, data and processes in generating better insights about diseases and how they can be treated, how medicines can be evaluated and funded, and how treatments can be better tailored to meet clinical needs. In particular, we will explore how evidence based therapeutic interventions, driven by innovation and improvements in technology, can yield better health outcomes for patients.

Chaired by Denis O’Driscoll, Superintendent Pharmacist for LloydsPharmacy Ireland, McKesson Ireland
- Hannes Toivane, Lead for Strategic Partnerships, Centre of Excellence for Innovation Nordics, Takeda
- Joe Keenan, Global Digital Health Solutions Director, Novartis
- Joan Byrne, Vice President, Science and Technology, Drug and Device, AbbVie
- Arup K. Roy, Vice President, BioProduct Research and Development, Eli Lilly
12:45
Panel discussion
13:00
Networking lunch
14:00
Factory 4.0: The New Manufacturing Sites
The traditional ‘factory floor’ is changing at pace. Machine learning, robotics, artificial intelligence, blockchain, big data and the internet of things are all causing a shift from a human-based ecosystem to a machine-driven digital one. These presentations and the discussion examine how digitalisation is transforming manufacturing sites and product process lifecycles. We will try to capture the impact of the fourth industrial revolution, or 4IR, on the biopharmaceutical industry, with a particular focus on the opportunities for Ireland in a global context.

Chaired by Ian Jones, Founder and CEO, Innopharma
- Karin Shanahan, SVP, Global Biologics and Sterile Operations, MSD
- Kieran Sheridan, Director, Global Manufacturing Systems, Alexion
- Ruth Beadle, Head of Vials Liquid/Lyo and Biologics Technology Group, Sanofi
- Alan Shefflin, Head, Digital Capability Management, Bristol-Myers Squibb
15:00
Panel discussion
15:15
Networking coffee break
15:45
Future-Fitting Biopharma for Best Societal Impact
These presentations and the discussion, chaired by PwC, explore the operating environment for biopharmaceutical innovators, drawing on experts’ analyses to identify improvement pathways across the medicines lifecycle. We will seek to sight opportunities to scale the industry in Ireland, especially in the area of advanced therapy medicinal products, with all actors, especially industry and the State, working together to maximise value in human health, in communities and in science.

Chaired by PwC
- Gary Hartnett, General Manager, Janssen Ireland Supply Chain
- Dr Ian Winburn, Global Medical Lead Haemophilia, Endocrine and IEM, Pfizer Biopharmaceuticals Group
- Dr Robert Grundy, Interim CEO, Health Innovation Research Alliance Northern Ireland
16:30
Panel discussion
16:45
Ireland: An Island at the Centre of the BioPharma World
Jim Greenwood, President and CEO, BIO
17:15
Close
Close